BOTHELL, Wash.–( BUSINESS WIRE )–Immunome, Inc. (The Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company’s Board of Directors (Compensation Committee) granted incentive awards that consists of optional stock options for the purchase of a total of 45,000 ordinary shares for four new employees under the Company’s 2024 Incentive Plan. The compensation committee approved the stock options as a material incentive for the employment of such employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $10.53 per share, which is the Company’s sales price on January 2, 2025, and will vest over four years, with 25% of the underlying shares vesting one year from of the applicable vesting start date and the balance of underlying shares that vest monthly for 36 months thereafter, depending on the new employees’ continued employment with the company through the applicable dates acquisition of rights. Stock options are subject to the terms and conditions of the Company’s 2024 Incentive Plan and the terms and conditions of the applicable stock option agreement covering the grant.
About Immunome
Immunome is a clinical targeted oncology company dedicated to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership previously instrumental in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our product portfolio includes AL102, a gamma secretase inhibitor currently in Phase 3 trials for the treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are subject to an IND that is expected to be submitted by the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not solely historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expectations regarding the progress of its process and the timing framework for submitting regulatory requests; and other forward-looking statements. These forward-looking statements are based on Immunome’s current expectations and include assumptions that may never be realized or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied by the statements due to a number of factors, including, but not limited to, the risks and uncertainties described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 , filed with the SEC on November 13, 2024, and in other filings by Immunome SEK Except as required by law, Immunome undertakes no obligation and does not intend to update any forward-looking statements included in this press release.
See the original version on businesswire.com: https://www.businesswire.com/news/home/20250102420836/en/
Contact with the investor
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
